CYP2C19 and Stroke: In secondary analysis of any ischaemic event (stroke or MI, n=1886 events in 7354 patients included in analysis) CYP2C19 LoF (*2-*8, intermediate/poor metabolisers) carriers were more likely to have an event while being prescribed clopidogrel than patients without CYP2C19 LoF genetic variants (HR 1.17, 95% CIs 1.06 to 1.29, p=0.002).